Owens & Minor Q3 GAAP EPS $0.16 vs $0.58 YoY; adjusted EBITDA margin up 140 bps

ACCENDRA HEALTH INC/VA/

2022-Q3 EPS reported $1.05 revenue$7,404,368,000

GAAP net income $12.5M ($0.16 EPS) vs $44.1M ($0.58 EPS) in Q3 2021; adjusted EPS $0.41 vs $0.74.
Revenue $2,497M, nearly flat YoY; adjusted EBITDA $127M, margin up 140 bps.
Patient Direct segment revenue grew 142% (11.4% pro forma for Apria); CPAP opportunities captured.
Products & Healthcare Services segment challenged by delayed customer reorders; accelerating key initiatives.
Generated $69M cash from operations in the quarter.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ACCENDRA HEALTH INC/VA/ reported the third quarter ended September 30, 2022 results: revenue $2,497, net income $12.5, EPS $0.16.

Period: the third quarter ended September 30, 2022
Revenue: $2,497
Net income: $12.5
EPS: $0.16
Result: reported results

Exact text from the filing

as our execution and market conditions improve,” Pesicka concluded. Financial Summary (1) ($ in millions, except per share data) 3Q22 3Q21 YTD 2022 YTD 2021 Revenue $2,497 $2,502 $7,404 $7,318 Operating income, GAAP $60.2 $62.9 $196.4 $306.5 Adj. Operating Income, Non-GAAP $83.4 $79.3 $301.9 $357.5 Net income, GAAP $12.5 $44.1 $80.4 $179.6 Adj. Net

View on SEC.gov

Browse all earnings releases →

ACCENDRA HEALTH INC/VA/ filing history →

Source: SEC EDGAR

accession 0000075252-22-000055

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.